Drug Profile


Alternative Names: Telcyta; TER 286; TLK 286

Latest Information Update: 10 Jul 2013

Price : $50

At a glance

  • Originator Telik
  • Class Antineoplastics; Oligopeptides; Small molecules
  • Mechanism of Action Glutathione transferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Diffuse large B cell lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer
  • Discontinued Breast cancer; Colorectal cancer

Most Recent Events

  • 10 Jul 2013 Canfosfamide is still available for licensing.
  • 05 Apr 2013 Telik terminates phase II trial in Diffuse large B cell lymphoma, Mantle cell lymphoma and Multiple myeloma in the USA (NCT01148108)
  • 31 Mar 2013 Suspended - Phase-III for Non-small cell lung cancer in Argentina, Australia, Brazil, Chile, Germany, Italy, UK and US (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top